Wang H.-Y.CHAO-CHI HOJIN-YUAN SHIH2020-08-132020-08-1320171556-0864https://www.scopus.com/inward/record.uri?eid=2-s2.0-85017656734&doi=10.1016%2fj.jtho.2017.01.009&partnerID=40&md5=6c8014004aaaef4655ac40c77b97da83https://scholars.lib.ntu.edu.tw/handle/123456789/512615[SDGs]SDG3anaplastic lymphoma kinase; anaplastic lymphoma kinase inhibitor; belizatinib; ceritinib; crizotinib; thyroid transcription factor 1; anaplastic lymphoma kinase; protein kinase inhibitor; protein tyrosine kinase; adrenal metastasis; adult; ALK gene; brain metastasis; bronchus biopsy; cancer resistance; cancer staging; case report; controlled study; drug dose sequence; drug response; EML4 gene; gene; gene rearrangement; genetic analysis; genotype; human; human cell; human tissue; immunohistochemistry; Letter; male; middle aged; non small cell lung cancer; pleura effusion; point mutation; reverse transcription polymerase chain reaction; RNA extraction; spinal cord metastasis; spleen metastasis; tumor growth; antagonists and inhibitors; drug resistance; enzymology; genetics; lung tumor; mutation; non small cell lung cancer; pathology; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinasesletter10.1016/j.jtho.2017.01.009284345152-s2.0-85017656734